Competitor Analysis: Emerging Diabetes Drugs

The present Competitive Intelligence Report about Emerging Diabetes Drugs provides a competitor evaluation in the field of novel molecules against a series of novel targets being developed for treatment of type 1 or 2 diabetes as of April 2011. Pharmacologic approaches include SGLT inhibitors, glucokinase activators, 11beta-HSD1 inhibitors and many others. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. In addition, the report lists company-specific R&D pipelines of emerging diabetes drugs in R&D. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.

Additional Information

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.